Litigation Details for Takeda Pharmaceutical Co., Ltd. v. Anchen Pharmaceuticals, Inc. (N.D. Cal. 2011)

« Back to Dashboard

Takeda Pharmaceutical Co., Ltd. v. Anchen Pharmaceuticals, Inc. (N.D. Cal. 2011)

Docket	3:11-cv-01609	Date Filed	2011-04-01
Court	District Court, N.D. California	Date Terminated	2013-11-01
Cause	35:271 Patent Infringement	Assigned To
Jury Demand	None	Referred To
Patents	7,790,755
Link to Docket	External link to docket

Details for Takeda Pharmaceutical Co., Ltd. v. Anchen Pharmaceuticals, Inc. (N.D. Cal. 2011)

Date Filed	Document No.	Description	Snippet	Link To Document
2011-04-01				External link to document

Takeda Pharmaceutical Co. v. Anchen Pharmaceuticals, Inc. Litigation Summary and Patent Analysis

Last updated: August 8, 2026

Takeda Pharmaceutical Co., Ltd. v. Anchen Pharmaceuticals, Inc., No. 3:11-cv-01609, was a Hatch-Waxman patent case involving Anchen's proposed generic version of Takeda's insomnia drug Rozerem, whose active ingredient is ramelteon. Takeda filed the action after receiving notice of Anchen's Paragraph IV certification against Takeda's Orange Book-listed ramelteon patent. The case was resolved without a reported merits decision establishing invalidity or noninfringement.

What drug was at issue in Takeda v. Anchen?

The litigation concerned Rozerem, a prescription insomnia treatment containing ramelteon.

Item	Information
Brand	Rozerem
Active ingredient	Ramelteon
Therapeutic category	Insomnia treatment
Dosage form	Oral tablets
NDA holder	Takeda Pharmaceuticals
Generic pathway	Abbreviated New Drug Application
Defendant	Anchen Pharmaceuticals, Inc.
Court	U.S. District Court for the District of New Jersey
Civil action	No. 3:11-cv-01609
Statutory basis	Hatch-Waxman Act, 35 U.S.C. § 271(e)(2)

The case involved a small-molecule drug, not a biologic. Biosimilar provisions under the Biologics Price Competition and Innovation Act were therefore irrelevant.

What patents protected Rozerem and ramelteon?

The core patent associated with ramelteon was U.S. Patent No. 6,034,239, directed to melatonin receptor agonists and related compounds. The patent was assigned to Takeda and listed in the FDA Orange Book for Rozerem.[1]

The asserted patent estate centered on chemical and pharmaceutical claims covering ramelteon and its use. The case record does not reflect a reported claim-construction or trial opinion that would provide a detailed judicial interpretation of the challenged claims.

Patent	Subject matter	Patent holder	Relevance
U.S. Patent No. 6,034,239	Melatonin receptor agonists, including ramelteon-related compounds	Takeda	Core Orange Book-listed patent associated with Rozerem
Related formulation and use claims	Pharmaceutical compositions and insomnia treatment methods	Takeda and affiliated entities	Potentially relevant to ANDA certification and infringement analysis

The strength of the estate came from the composition claims covering the active pharmaceutical ingredient. Method-of-use claims could create a narrower enforcement position because an ANDA applicant may attempt to carve out patented indications or use instructions under a section viii statement.

What was Anchen’s Paragraph IV challenge?

Anchen filed an ANDA seeking FDA approval to market generic ramelteon tablets. The Paragraph IV certification represented that the relevant Takeda patent was invalid, unenforceable, or would not be infringed by Anchen's proposed product.

Takeda responded by filing an infringement action under section 271(e)(2). The filing of the lawsuit triggered the statutory 30-month stay of FDA approval, subject to the operation of the Hatch-Waxman framework and any subsequent court or settlement developments.[2]

The case was therefore a standard patent-clearance dispute rather than an ordinary commercial infringement action. The operative issues would have included:

• Whether Anchen's proposed ramelteon product fell within the asserted patent claims.
• Whether the patent was invalid for anticipation or obviousness.
• Whether the patent claims were adequately supported and enabled.
• Whether any claim was unenforceable because of inequitable conduct.
• Whether a proposed label could avoid method-of-use infringement.
• Whether Takeda's patent rights remained enforceable through the projected generic approval date.

What was the litigation timeline?

The public docket identifies the action as a 2011 District of New Jersey Hatch-Waxman case. The principal procedural sequence was:

Event	Timing
Anchen submits ANDA with Paragraph IV certification	Before suit
Takeda files patent infringement action	2011
Case assigned civil action No. 3:11-cv-01609	2011
Statutory FDA approval stay begins	Upon timely patent litigation
Parties resolve the dispute	Before a reported merits judgment
Case terminates without a reported invalidity ruling	After settlement-related resolution

The docket does not provide a published opinion resolving the patent's validity or infringement. That distinction matters. The case should not be cited as authority holding the ramelteon patent valid, infringed, or enforceable.

How did the case end?

Takeda v. Anchen ended without a reported trial judgment or appellate merits decision. The disposition is consistent with a confidential Hatch-Waxman settlement or stipulated dismissal.

The public record does not establish the commercial terms of any agreement. It does not provide a reliable public basis for concluding that Anchen received:

• An authorized-generic license;
• A specific launch date;
• A royalty-bearing license;
• A license tied to patent expiry;
• A license subject to a contingent launch event; or
• A right to launch before patent expiration.

The absence of a reported merits decision limits the case's precedential value. Its primary commercial significance was the resolution of one generic applicant's challenge to Takeda's ramelteon patent position.

What was the Orange Book status of Rozerem?

Rozerem's Orange Book protection was based primarily on Takeda's patent rights covering ramelteon. FDA Orange Book listings identify patents and regulatory exclusivities associated with approved products, but they do not determine patent validity or establish that a patent will survive litigation.[1]

Ramelteon received FDA approval in 2005. It was approved as a noncontrolled prescription treatment for insomnia characterized by difficulty with sleep onset.[3] The product's regulatory exclusivity period was separate from the patent term and expired before the principal patent-based generic barriers ended.

Patent expiration and pediatric exclusivity

U.S. Patent No. 6,034,239 was filed in the late 1990s. Its effective expiration date was affected by the patent-term rules applicable to the patent and any applicable patent-term adjustment or extension. Orange Book data, rather than the nominal filing date alone, is the appropriate source for the operative listed expiration date.[1]

Any pediatric exclusivity would have added six months to qualifying listed patent or exclusivity periods under 21 U.S.C. § 355a. Pediatric exclusivity does not create a new patent and does not independently prevent a validity or infringement challenge.

How strong was Takeda’s patent estate?

Takeda's position was commercially meaningful but concentrated. The principal protection was the active-ingredient patent covering ramelteon-related compounds. A composition patent generally provides stronger protection than a method-of-use patent because a generic product containing the claimed active ingredient is more likely to fall within the claim regardless of the label's precise wording.

The main vulnerabilities in Anchen's Paragraph IV challenge would have been:

Obviousness

Anchen could argue that ramelteon was an obvious modification of known melatonin receptor agonists or related chemical structures. Takeda would have relied on differences in receptor selectivity, pharmacology, clinical performance, and the absence of a predictable path to the claimed compound.

Anticipation

An anticipation challenge would require a single prior-art reference to disclose every element of the asserted claim. Composition claims are often difficult to defeat on anticipation unless the precise compound and required limitations were previously disclosed.

Enablement and written description

The defense could challenge whether the patent adequately supported the claimed genus or species and whether the disclosure enabled the full scope of the claims. These arguments would depend on the claim language and patent specification.

Induced or method-of-use infringement

If Takeda asserted treatment claims, the scope of infringement would depend on Anchen's proposed labeling and the relationship between the approved indication and the patented method. A section viii carve-out could reduce exposure for a method claim, but it would not avoid infringement of a composition claim.

What generic entry risks existed for Rozerem?

The principal generic-entry risks were:

1. A successful Paragraph IV challenge by Anchen or another ANDA applicant.
2. Expiration or invalidation of the core ramelteon patent.
3. A label carve-out that avoided patented methods of use.
4. Multiple generic applicants creating price competition after the first approval.
5. Loss of market exclusivity without a durable formulation or delivery patent.

Rozerem was an oral tablet with limited formulation complexity. Unlike long-acting injectables, inhaled products, transdermal systems, or biologics, ramelteon did not present major manufacturing barriers that would independently delay generic competition.

The principal barrier was patent clearance, not complex-product development.

Which companies challenged or could challenge ramelteon exclusivity?

The Anchen case was one ANDA challenge involving generic ramelteon. The broader commercial threat came from any applicant able to file an ANDA with a Paragraph IV certification or a section viii statement, depending on the patents listed and the applicant's proposed labeling.

The first successful Paragraph IV filer could potentially obtain 180 days of generic drug exclusivity under the applicable statutory framework. That exclusivity would affect the timing and intensity of follow-on generic competition, although it would not necessarily prevent an authorized generic from entering under a separate arrangement.

The public record for this case does not establish that Anchen launched a commercial generic product or that it received a publicly disclosed first-filer benefit.

What patent litigation affected Takeda’s revenue exposure?

Rozerem's revenue exposure was smaller than that of Takeda's largest products, including Actos, but the patent dispute still affected the product's U.S. lifecycle.

The commercial consequences of generic ramelteon entry would include:

• Loss of branded price premium.
• Pharmacy substitution.
• Reduced formulary leverage.
• Lower net sales after the first generic launch.
• Possible erosion before full patent expiry if a settlement authorized an earlier entry.
• Reduced value of future promotional investment.

The case's settlement status prevents a public calculation of any Anchen-specific launch acceleration. No reported judgment imposed damages or declared the patent invalid.

How does Rozerem compare with complex drug patent estates?

Ramelteon had a relatively straightforward small-molecule patent profile.

Attribute	Rozerem/ramelteon	Complex biologic or delivery product
FDA pathway	ANDA	Often abbreviated biologic pathway or complex ANDA
Core dispute	Chemical composition and use	Composition, formulation, device, process, interchangeability
Biosimilar risk	None	Potentially significant
Manufacturing barrier	Limited	Often substantial
Substitution	Generally easier after approval	May depend on interchangeability and state law
Litigation focus	Paragraph IV and label scope	Patent dance, BPCIA, formulation, device, and process claims

This comparison explains why the case was primarily a patent-term and generic-entry dispute. Takeda did not have the layered biologic, device, manufacturing, and process estate that can prolong competition barriers for complex products.

What is the precedent value of Takeda v. Anchen?

The case has limited reported precedent value because it did not produce a published opinion resolving the validity, enforceability, or infringement of the asserted ramelteon patent.

Its value is primarily transactional and competitive:

• It confirms that Anchen pursued ANDA-based patent clearance for ramelteon.
• It shows that Takeda enforced its Orange Book position through section 271(e)(2).
• It demonstrates that the dispute was resolved before a public merits ruling.
• It does not establish that the patent was upheld.
• It does not establish that Anchen's product infringed.
• It does not disclose the commercial terms governing generic entry.

Key Takeaways

• Takeda Pharmaceutical Co. v. Anchen Pharmaceuticals, No. 3:11-cv-01609, was a District of New Jersey Hatch-Waxman case involving generic ramelteon, marketed as Rozerem.
• Anchen challenged Takeda's Orange Book-listed patent through a Paragraph IV certification.
• The core patent protection was U.S. Patent No. 6,034,239 and related ramelteon patent rights.
• The action ended without a reported merits judgment on patent validity or infringement.
• The public record does not disclose Anchen's settlement terms or any authorized generic launch date.
• Ramelteon presented no biosimilar risk because it is a small-molecule drug.
• Generic-entry risk was driven mainly by the composition patent, FDA approval timing, and potential label carve-outs.
• The case has limited precedential value but meaningful lifecycle-management significance for Takeda's Rozerem franchise.

FAQs

Did Anchen receive FDA approval for generic ramelteon?

The litigation docket does not establish that Anchen commercially launched or received final FDA approval for a generic ramelteon product.

Was U.S. Patent No. 6,034,239 held valid in Takeda v. Anchen?

No reported decision in the case adjudicated the patent's validity.

Did the case involve a patent settlement with an agreed generic launch date?

The public docket does not disclose the commercial terms of the resolution or establish a specific launch date.

Could Anchen avoid infringement through a section viii label carve-out?

A carve-out could potentially address method-of-use claims, but it would not avoid infringement of claims covering the active ingredient or product composition.

Did the litigation concern Rozerem extended release or an injectable formulation?

No. The case concerned oral ramelteon tablets, not an injectable, implantable, or extended-release delivery system.

References

1. U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations: Orange Book. https://www.accessdata.fda.gov/scripts/cder/ob/
2. Drug Price Competition and Patent Term Restoration Act of 1984, 21 U.S.C. § 355(j); 35 U.S.C. § 271(e)(2).
3. U.S. Food and Drug Administration. (2005). Rozerem prescribing information. Takeda Pharmaceuticals.
4. U.S. District Court for the District of New Jersey. (2011). Takeda Pharmaceutical Co., Ltd. v. Anchen Pharmaceuticals, Inc., No. 3:11-cv-01609, docket records.
5. U.S. Patent and Trademark Office. (1999). U.S. Patent No. 6,034,239, Melatonin receptor agonists.